Updated 18 March 2025
| Table 1. Total time for completed cases | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for closed cases | No. of drug IDs | |||||
| 1st quarter 2023 | 143 | 240 | -97 | 2 | 2 | 100 |
| 2nd quarter 2023 | 289 | 240 | 49 | 1 | 0 | 0 |
| 3rd quarter 2023 | 391 | 240 | 151 | 5 | 1 | 20 |
| 4th quarter 2023 | 422 | 240 | 182 | 1 | 0 | 0 |
| 1st quarter 2024 | 240 | 0 | ||||
| 2nd quarter 2024 | 266 | 240 | 26 | 4 | 3 | 75 |
| 3rd quarter 2024 | 280 | 240 | 40 | 7 | 1 | 14 |
| 4th quarter 2024 | 265 | 240 | 25 | 9 | 7 | 78 |
| Table 2. Total time for completed cases - Human medicines | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for closed cases - HUM | No. of drug IDs | |||||
| 1st quarter 2023 | 143 | 240 | -97 | 2 | 2 | 100 |
| 2nd quarter 2023 | 240 | 0 | ||||
| 3rd quarter 2023 | 431 | 240 | 191 | 4 | 0 | 0 |
| 4th quarter 2023 | 422 | 240 | 182 | 1 | 0 | 0 |
| 1st quarter 2024 | 240 | 0 | ||||
| 2nd quarter 2024 | 266 | 240 | 26 | 4 | 3 | 75 |
| 3rd quarter 2024 | 280 | 240 | 40 | 7 | 1 | 14 |
| 4th quarter 2024 | 265 | 240 | 25 | 9 | 7 | 78 |
| Table 3. Total time for completed cases - Veterinary medicines | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for closed cases - VET | No. of drug IDs | |||||
| 1st quarter 2023 | 240 | 0 | ||||
| 2nd quarter 2023 | 289 | 240 | 49 | 1 | 0 | 0 |
| 3rd quarter 2023 | 234 | 240 | -6 | 1 | 1 | 100 |
| 4th quarter 2023 | 240 | 0 | ||||
| 1st quarter 2024 | 240 | 0 | ||||
| 2nd quarter 2024 | 240 | 0 | ||||
| 3rd quarter 2024 | 240 | 0 | ||||
| 4th quarter 2024 | 240 | 0 | ||||
| Table 4. Start-up phase for completed cases | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for completed cases | No. of drug IDs | |||||
| 1st quarter 2023 | 3 | 30 | -27 | 2 | 2 | 100 |
| 2nd quarter 2023 | 1 | 30 | -29 | 1 | 1 | 100 |
| 3rd quarter 2023 | 25 | 30 | -5 | 5 | 2 | 40 |
| 4th quarter 2023 | 114 | 30 | 84 | 1 | 0 | 0 |
| 1st quarter 2024 | 30 | 0 | ||||
| 2nd quarter 2024 | 32 | 30 | 2 | 4 | 3 | 75 |
| 3rd quarter 2024 | 11 | 30 | -19 | 7 | 7 | 100 |
| 4th quarter 2024 | 24 | 30 | -6 | 9 | 6 | 67 |
| Table 5. Start-up phase for completed cases - Human medicines | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for completed cases - HUM | No. of drug IDs | |||||
| 1st quarter 2023 | 3 | 30 | -27 | 2 | 2 | 100 |
| 2nd quarter 2023 | 30 | 0 | ||||
| 3rd quarter 2023 | 24 | 30 | -6 | 4 | 1 | 25 |
| 4th quarter 2023 | 114 | 30 | 84 | 1 | 0 | 0 |
| 1st quarter 2024 | 30 | 0 | ||||
| 2nd quarter 2024 | 32 | 30 | 2 | 4 | 3 | 75 |
| 3rd quarter 2024 | 11 | 30 | -19 | 7 | 7 | 100 |
| 4th quarter 2024 | 24 | 30 | -6 | 9 | 6 | 67 |
| Table 6. Start-up phase for completed cases - Veterinary medicines | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for completed cases - VET | No. of drug IDs | |||||
| 1st quarter 2023 | 30 | 0 | ||||
| 2nd quarter 2023 | 1 | 30 | -29 | 1 | 1 | 100 |
| 3rd quarter 2023 | 27 | 30 | -3 | 1 | 1 | 100 |
| 4th quarter 2023 | 30 | 0 | ||||
| 1st quarter 2024 | 30 | 0 | ||||
| 2nd quarter 2024 | 30 | 0 | ||||
| 3rd quarter 2024 | 30 | 0 | ||||
| 4th quarter 2024 | 30 | 0 | ||||
| Table 7. Assessment time for remaining phases | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for assessment and closing phase | No. of drug IDs | |||||
| 1st quarter 2023 | 140 | 210 | -70 | 2 | 2 | 100 |
| 2nd quarter 2023 | 288 | 210 | 78 | 1 | 0 | 0 |
| 3rd quarter 2023 | 367 | 210 | 157 | 5 | 1 | 20 |
| 4th quarter 2023 | 308 | 210 | 98 | 1 | 0 | 0 |
| 1st quarter 2024 | 210 | 0 | ||||
| 2nd quarter 2024 | 234 | 210 | 24 | 4 | 3 | 75 |
| 3rd quarter 2024 | 269 | 210 | 59 | 7 | 1 | 14 |
| 4th quarter 2024 | 242 | 210 | 32 | 9 | 1 | 11 |
| Table 8. Assessment time for remaining phases - Human medicines | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for assessment and closing phase - HUM | No. of drug IDs | |||||
| 1st quarter 2023 | 140 | 210 | -70 | 2 | 2 | 100 |
| 2nd quarter 2023 | 210 | 0 | ||||
| 3rd quarter 2023 | 407 | 210 | 197 | 4 | 0 | 0 |
| 4th quarter 2023 | 308 | 210 | 98 | 1 | 0 | 0 |
| 1st quarter 2024 | 210 | 0 | ||||
| 2nd quarter 2024 | 234 | 210 | 24 | 4 | 3 | 75 |
| 3rd quarter 2024 | 269 | 210 | 59 | 7 | 1 | 14 |
| 4th quarter 2024 | 242 | 210 | 32 | 9 | 1 | 11 |
| Table 9. Assessment time for remaining phases - Veterinary medicines | ||||||
| Average assessment time | Target days for full/abridged applications | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Total assessment times for assessment and closing phase - VET | No. of drug IDs | |||||
| 1st quarter 2023 | 210 | 0 | ||||
| 2nd quarter 2023 | 288 | 210 | 78 | 1 | 0 | 0 |
| 3rd quarter 2023 | 207 | 210 | -3 | 1 | 1 | 100 |
| 4th quarter 2023 | 210 | 0 | ||||
| 2nd quarter 2024 | 210 | 0 | ||||
| 3rd quarter 2024 | 210 | 0 | ||||
| 4th quarter 2024 | 210 | 0 | ||||
| 4th quarter 2024 | 210 | 0 | ||||
| Table 10. Start-up phase for initiated procedures | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for initiated procedures | No. of drug IDs | |||||
| 1st quarter 2023 | 32 | 30 | 2 | 1 | 0 | 0 |
| 2nd quarter 2023 | 30 | 0 | ||||
| 3rd quarter 2023 | 38 | 30 | 8 | 1 | 0 | 0 |
| 4th quarter 2023 | 25 | 30 | -5 | 1 | 1 | 100 |
| 1st quarter 2024 | 6 | 30 | -24 | 1 | 1 | 100 |
| 2nd quarter 2024 | 49 | 30 | 19 | 1 | 0 | 0 |
| 3rd quarter 2024 | 56 | 30 | 26 | 4 | 1 | 25 |
| 4th quarter 2024 | 21 | 30 | -9 | 2 | 2 | 100 |
| Table 11. Start-up phase for initiated procedures - Human medicines | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for initiated procedures - HUM | No. of drug IDs | |||||
| 1st quarter 2023 | 32 | 30 | 2 | 1 | 0 | 0 |
| 2nd quarter 2023 | 30 | 0 | ||||
| 3rd quarter 2023 | 38 | 30 | 8 | 1 | 0 | 0 |
| 4th quarter 2023 | 25 | 30 | -5 | 1 | 1 | 100 |
| 1st quarter 2024 | 6 | 30 | -24 | 1 | 1 | 100 |
| 2nd quarter 2024 | 49 | 30 | 19 | 1 | 0 | 0 |
| 3rd quarter 2024 | 53 | 30 | 23 | 3 | 1 | 33 |
| 4th quarter 2024 | 21 | 30 | -9 | 2 | 2 | 100 |
| Table 12. Start-up phase for initiated procedures - Veterinary medicines | ||||||
| Average assessment time | Target days | Difference between assessment time and target days | No. of cases measured | No. of cases within target | Share of cases within target in per cent | |
| Start-up phase for initiated procedures - VET | No. of drug IDs | |||||
| 1st quarter 2023 | 30 | 0 | ||||
| 2nd quarter 2023 | 30 | 0 | ||||
| 3rd quarter 2023 | 30 | 0 | ||||
| 4th quarter 2023 | 30 | 0 | ||||
| 1st quarter 2024 | 30 | 0 | ||||
| 2nd quarter 2024 | 30 | 0 | ||||
| 3rd quarter 2024 | 67 | 30 | 37 | 1 | 0 | 0 |
| 4th quarter 2024 | 30 | 0 | ||||